The Barcelona Brain Health Initiative is a longitudinal cohort study that began in 2017 and aims to understand and characterize the determinants of brain health maintenance in middle aged adults. A cohort of 4686 individuals between the ages of 40 and 65 years free from any neurological or psychiatric diseases was established, and we collected extensive demographic, socio-economic information along with measures of self-perceived health and lifestyles (general health, physical activity, cognitive activity, socialization, sleep, nutrition and vital plan). Here we report on the baseline characteristics of the participants, and the results of the one-year follow-up evaluation. Participants were mainly women, highly educated, and with better lifestyles compared with the general population. After one year 60% of participants completed the one-year follow-up, and these were older, with higher educational level and with better lifestyles in some domains. In the absence of any specific interventions to-date, these participants showed small improvements in physical activity and sleep, but decreased adherence to a Mediterranean diet. These changes were negatively associated with baseline scores, and poorer habits at baseline were predictive of an improvement in lifestyle domains. Of the 2353 participants who completed the one-year follow-up, 73 had been diagnosed with new neurological and neuropsychiatric diseases. Changes in vital plan at follow-up, as well as gender, sleep quality and sense of coherence at baseline were shown to be significant risk factors for the onset of these diagnoses. Notably, gender risk factor decreased in importance as we adjusted by sleep habits, suggesting its potential mediator effects. These findings stress the importance of healthy lifestyles in sustaining brain health, and illustrate the individual benefit that can be derived from participation in longitudinal observational studies. Modifiable lifestyles, specifically quality of sleep, may partially mediate the effect of other risk factors in the development of some neuropsychiatric conditions., Competing Interests: We have the following interests: Dr. A. Pascual-Leone serves on the scientific advisory boards for Neuronix, Starlab Neuroscience, Neuroelectrics, Magstim, Magventure, Constant Therapy, and Neosync; and is listed as an inventor on several issued and pending patents on the real-time integration of transcranial magnetic stimulation with electroencephalography and magnetic resonance imaging: 1. Method and Apparatus for Recording an Electroencephalogram During Transcranial Magnetic Stimulation. US 6,266,556 B1. (Application 09/067,111; filed Apr 27, 1998) 2. Method and Apparatus for Monitoring a Magnetic Resonance Image During Transcranial Magnetic Stimulation. US 6,198,958 B1. (Application 09/096,725; filed Jan 11, 1998) 3. Method and Apparatus for Recording an Electroencephalogram During Transcranial Magnetic Stimulation.US 6,571,123 B2.(Application 09/746,055; filed Dec 21, 2000; prior publication data US 2002/0007128 A1 Jan 17, 2002) 4. A. Pascual-Leone And T. Wagner. Transcranial Magnetic Stimulation (TMS) Methods and Apparatus.US 2010/0113959 A1. (Application 10/731892; filed Dec 9. 2003) 5. System and Methods for Applying Signals, Including Contralesional Signals, to Neural Populations. US 2007/0288072 A1. (Application 11/697,696l filed Apr 6, 2007) 6. Transcranial Magnetic Stimulation Methods and Apparatus. US 2010/0210894 A1 2007 Dec 1. 7. Method and System for Safely Guide Interventions in a Procedure where the Substrate is Neural Plasticity. (International Application PCT/ES2008/000677; filed Oct 31, 2008; corresponding US Application US 2011213213. 8. Methods for treating and/or collecting information regarding neurological disorders, including language disorders. US 7,565,199 B2. (Application 10/731,892; filed Dec 9, 2003; provisional application 60/432,073; filed Dec 9, 2002) 9. Method and System for Treating Amblyopia. US 13/200,080. (UR 1-11030- 10035; filed Sept 16, 2010) 10. Non-invasive methods for evaluating cortical plasticity impairments. US 2011/0224571 A1 (Application 12/947491; filed Nov 16, 2010) 11. Methods for treating and/or collecting information regarding neurological disorders, including language disorders. US 08050767. (Application 11/935135; filed November 5, 2007) 12. Device for treating human vision using combined optical and electrical stimulation. (Application 12/883,423; filed Sep 16, 2010; provisional application 60/886,073; filed Jan 22, 2007) 13. A Method for Treating Neuropathic Pain. (Application 13/197,883; filed Aug 4, 2011) 14. Identification of optimized therapeutic TMS targets for depression based on functional connectivity MRI (USSN provisional application 61/648,032 filed May 16, 2012) 15. System and Method for Treating Neuropathic Pain. (Application EP12380025; filed May 18, 2012) 16. Transcranial magnetic stimulation (TMS) methods and apparatus.- US Patent 20,130,338,424, 2013 17. A method and a system for optimizing the configuration of multisite Transcranial current stimulation and a computer-readable medium. US nº 14/058,517 (Filed Oct 21, 2013) 18. Identifying Individual Target Sites for Transcranial Magnetic Stimulation Applications. Application Number 14/401,296; Filed November 14, 2014. However, their potential field of exploitation is not related with the content of the manuscript. Josep M. Tormos is a listed co-inventor in the following patents: 1. A method for treating neuropatic pain (US 13/197,883) 2. Method and system to safely guide interventions in procedures the substrate whereof is neural plasticity (PCT/ES2008/000677) However, he has no ownership of the industrial property for those patents nor is their potential field of exploitation related with the content of the manuscript. Ad-Salutem Institute, Sodexo S.A., I.C.A Informática y Comunicaciones Avanzadas, Neuroelectrics, Corporació Catalana de Mitjans Audiovisuals, Club Metropolitan, Casa Ametller, and Agència de Qualitat i Avaluació Sanitàries de Catalunya-AQuAS are commercial companies supporting the Barcelona Brain Health Initiative and this study. There are no further patents, products in development or marketed products to declare. This does not alter our adherence to all the PLOS ONE policies on sharing data and materials.